EMEDZ.NET

Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Reserpine (Serpasil) - Uses, Dose, Side effects, Brands

Reserpine reduces blood pressure via depletion of sympathetic biogenic amines (norepinephrine and dopamine).

Reserpine (Serpasil) Uses:

Agitated psychotic states:
- It is used in the treatment of agitated psychotic states (schizophrenia)
Hypertension:
- It is used in the treatment of mild to moderate hypertension.
- It is not recommended for the initial treatment of hypertension.

Reserpine (Serpasil) Dose in Adults:

Reserpine tablets are no longer available in the US.

Reserpine (Serpasil) Dosage as an alternative agent in the treatment of Hypertension:

The initial dose is 0.1 mg once daily
Then titrate as needed based on patient response up to 0.25 mg once daily
Clinically, the need for a "loading" period (as recommended by the manufacturer) is not supported well, and the above dosing is preferred.

Reserpine (Serpasil) Dosage in the treatment of Schizophrenia:

Dosing recommendations usually vary
initial dose recommendations range from 0.05 to 0.25 mg.
It may be increased in increments of 0.1 to 0.25 mg

Reserpine (Serpasil) Dose in Children

The safety and efficacy of reserpine in children is not established.

Reserpine pregnancy Risk Factor C

It can also cross the placenta.
In animal reproduction studies using parenteral administration, teratogenic events were observed.
The non-teratogenic effects of reserpine on newborns could include anorexia and cyanosis as well as increased secretions in the respiratory tract.

Use while breastfeeding

It can be found in breast milk
Breastfed infants have experienced anorexia and cyanosis, as well as increased secretions of their respiratory tract.

Reserpine (Serpasil) dose in Renal disease:

The manufacturer's label does not include any dosage adjustments.
Some experts have used the following dosing adjustments:
CrCl 10mL/minute
- Avoid excessive usage
Peritoneal dialysis and hemoodialysis
- Hemo- or peritoneal dialysis cannot remove it
- Supplemental dosages are not required.

Serpasil dose in liver disease:

No dosage adjustment is given in the manufacturer’s labeling.

Side effects of Reserpine (Serpasil):

Cardiovascular:
- Bradycardia
- Cardiac Arrhythmia
- Chest Pain
- Flushing
- Hypotension
- Peripheral Edema
- Syncope
- Ventricular Premature Contractions
Central Nervous System:
- Anxiety (Paradoxical)
- Decreased Mental Acuity
- Depression
- Dizziness
- Drowsiness
- Drug-Induced Parkinson’s Disease
- Fatigue
- Headache
- Nightmares
- Nervousness
Dermatologic:
- Pruritus
- Skin Rash
Endocrine & Metabolic:
- Gynecomastia
- Decreased Libido
- Weight Gain
Gastrointestinal:
- Anorexia
- Diarrhea
- Hyperacidity
- Nausea
- Sialorrhea
- Vomiting
- Xerostomia
Genitourinary:
- Impotence
Hematologic & Oncologic:
- Immune Thrombocytopenia
- Purpura
Neuromuscular & Skeletal:
- Myalgia
Ophthalmic:
- Blurred Vision
- Optic Atrophy
Respiratory:
- Dyspnea
- Epistaxis
- Nasal Congestion

Contraindication to Reserpine (Serpasil):

Hypersensitivity to any component of the drug/preparation
Active peptic ulcer disease, and ulcerative colitis
History of mental depression, especially with suicidal tendencies
Patients who have received electroconvulsive treatment (ECT)

Warnings and precautions

CNS effects
- High doses can cause severe mental depression, anxiety, and psychosis (uncommon with dosages below 0.25 mg/day).
Orthostatic hypotension
- It can lead to orthostatic hypotension
- Use caution in patients at high risk of hypotension, or patients with transient hypotensive episodes that are difficult to tolerate (cardiovascular disease and cerebrovascular disease).
Asthma
- Use caution in patients suffering from asthma.
Gallstones
- Patients with gallstones should be treated with caution
Gastrointestinal Disease:
- Patients with inflammatory bowel disease and a history of peptic ulcer disease should be cautious.
Parkinson disease
- Patients with Parkinson's disease should be treated with caution
Renal impairment
- Patients with impaired renal function should be cautious.

Reserpine (United States: Not available): Drug Interaction

Risk Factor C (Monitor therapy)
Acebrophylline	May enhance the tachycardic effect of Reserpine.
Alcohol (Ethyl)	CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).
Alfuzosin	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Alizapride	May enhance the CNS depressant effect of CNS Depressants.
Amezinium	May enhance the adverse/toxic effect of Reserpine.
Amphetamines	Gastrointestinal Acidifying Agents may decrease the serum concentration of Amphetamines.
Amphetamines	May diminish the antihypertensive effect of Antihypertensive Agents.
Antipsychotic Agents (Second Generation [Atypical])	Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).
Barbiturates	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Benperidol	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Beta-Blockers	Reserpine may enhance the hypotensive effect of Beta-Blockers.
Brexanolone	CNS Depressants may enhance the CNS depressant effect of Brexanolone.
Brigatinib	May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.
Brimonidine (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Brimonidine (Topical)	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Bromopride	May enhance the CNS depressant effect of CNS Depressants.
Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Cannabis	May enhance the CNS depressant effect of CNS Depressants.
Cardiac Glycosides	Reserpine may enhance the adverse/toxic effect of Cardiac Glycosides.
Chlorphenesin Carbamate	May enhance the adverse/toxic effect of CNS Depressants.
CNS Depressants	May enhance the adverse/toxic effect of other CNS Depressants.
Dexmethylphenidate	May diminish the therapeutic effect of Antihypertensive Agents.
Diazoxide	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Dimethindene (Topical)	May enhance the CNS depressant effect of CNS Depressants.
Doxylamine	May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended.
Dronabinol	May enhance the CNS depressant effect of CNS Depressants.
DULoxetine	Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine.
Esketamine	May enhance the CNS depressant effect of CNS Depressants.
Herbs (Hypertensive Properties)	May diminish the antihypertensive effect of Antihypertensive Agents.
Herbs (Hypotensive Properties)	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
HydrOXYzine	May enhance the CNS depressant effect of CNS Depressants.
Hypotension-Associated Agents	Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents.
Kava Kava	May enhance the adverse/toxic effect of CNS Depressants.
Levodopa-Containing Products	Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Containing Products.
Lofexidine	May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.
Lormetazepam	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Magnesium Sulfate	May enhance the CNS depressant effect of CNS Depressants.
Methylphenidate	May diminish the antihypertensive effect of Antihypertensive Agents.
MetyroSINE	CNS Depressants may enhance the sedative effect of MetyroSINE.
Minocycline	May enhance the CNS depressant effect of CNS Depressants.
Mirtazapine	CNS Depressants may enhance the CNS depressant effect of Mirtazapine.
Molsidomine	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Nabilone	May enhance the CNS depressant effect of CNS Depressants.
Naftopidil	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Nicergoline	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Nicorandil	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Nitroprusside	Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside.
Pentoxifylline	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Pholcodine	Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine.
Phosphodiesterase 5 Inhibitors	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Piribedil	CNS Depressants may enhance the CNS depressant effect of Piribedil.
Pizotifen	May diminish the antihypertensive effect of Reserpine.
Pramipexole	CNS Depressants may enhance the sedative effect of Pramipexole.
Prostacyclin Analogues	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
Quinagolide	May enhance the hypotensive effect of Blood Pressure Lowering Agents.
QuiNIDine	Reserpine may enhance the adverse/toxic effect of QuiNIDine.
ROPINIRole	CNS Depressants may enhance the sedative effect of ROPINIRole.
Rotigotine	CNS Depressants may enhance the sedative effect of Rotigotine.
Rufinamide	May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.
Selective Serotonin Reuptake Inhibitors	CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.
Tetrahydrocannabinol	May enhance the CNS depressant effect of CNS Depressants.
Tetrahydrocannabinol and Cannabidiol	May enhance the CNS depressant effect of CNS Depressants.
Trimeprazine	May enhance the CNS depressant effect of CNS Depressants.
Yohimbine	May diminish the antihypertensive effect of Antihypertensive Agents.
Risk Factor D (Consider therapy modification)
Amifostine	Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.
Blonanserin	CNS Depressants may enhance the CNS depressant effect of Blonanserin.
Buprenorphine	CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.
Chlormethiazole	May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.
Cladribine	Inhibitors of Equilibrative Nucleoside (ENT1) and Concentrative Nucleoside (CNT3) Transport Proteins may increase the serum concentration of Cladribine. Management: Avoid concomitant use of ENT1 or CNT3 inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider an ENT1 or CNT3 inhibitor dose reduction and separation in the timing of administration.
Droperidol	May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs.
Flunitrazepam	CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.
HYDROcodone	CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Methotrimeprazine	CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.
Monoamine Oxidase Inhibitors	May enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension). Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.
Obinutuzumab	May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.
Opioid Agonists	CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
OxyCODONE	CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Perampanel	May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.
Sodium Oxybate	May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.
Suvorexant	CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.
Tapentadol	May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.
Zolpidem	CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.
Risk Factor X (Avoid combination)
Azelastine (Nasal)	CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).
Bromperidol	Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents.
Bromperidol	May enhance the CNS depressant effect of CNS Depressants.
Deutetrabenazine	Reserpine may enhance the adverse/toxic effect of Deutetrabenazine.
Iobenguane Radiopharmaceutical Products	Reserpine may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer reserpine until at least 7 days after each iobenguane dose.
Orphenadrine	CNS Depressants may enhance the CNS depressant effect of Orphenadrine.
Oxomemazine	May enhance the CNS depressant effect of CNS Depressants.
Paraldehyde	CNS Depressants may enhance the CNS depressant effect of Paraldehyde.
Tetrabenazine	Reserpine may enhance the adverse/toxic effect of Tetrabenazine.
Thalidomide	CNS Depressants may enhance the CNS depressant effect of Thalidomide.

Monitor:

Blood pressure, standing and sitting/supine

How to administer Reserpine?

It may be administered with or without meals orally.

Mechanism of action of Reserpine (Serpasil):

It lowers blood pressure by depleting sympathetic biogenic amines (norepinephrine, dopamine).
Sedative effects are also common.

Onset of action:

Antihypertensive effect: 3-6 days

Duration:

2-6 weeks

Absorption:

almost 40%

Protein binding:

Metabolism:

mainly hepatic (>90%)

Half-life elimination:

50-100 hours

Excretion:

From Feces (30% to 60%) & urine (10%)

International Brands of Reserpine:

Raupasil
Rauserpine
Rauverid
Reselpin
Respine
Serpalan
Serpasil

Reserpine (Serpasil) Brand Names in Pakistan:

Reserpine Tablets 0.25 mg
Reserpine	Specific Research Laboratories

Comments

NO Comments Found

Escitalopram in Pakistan
13-12-2021

Is Celexa safe in Pregnancy?
13-12-2021

Zonisamide (Zonegran) - Uses, Dosages, Brands
13-12-2021

Zopiclone - For the short-term treatment of insomnia
13-12-2021

Disclaimer Notice:

Emedz.net is not an online pharmacy:

We are not affiliated with any pharmaceutical companies:

Reserpine (Serpasil) - Uses, Dose, Side effects, Brands

Reserpine (Serpasil) Uses:

Agitated psychotic states:

Hypertension:

Reserpine (Serpasil) Dose in Adults:

Reserpine (Serpasil) Dosage as an alternative agent in the treatment of Hypertension:

Reserpine (Serpasil) Dosage in the treatment of Schizophrenia:

Reserpine (Serpasil) Dose in Children

Reserpine pregnancy Risk Factor C

Use while breastfeeding

Reserpine (Serpasil) dose in Renal disease:

Serpasil dose in liver disease:

Side effects of Reserpine (Serpasil):

Cardiovascular:

Central Nervous System:

Dermatologic:

Endocrine & Metabolic:

Gastrointestinal:

Genitourinary:

Hematologic & Oncologic:

Neuromuscular & Skeletal:

Ophthalmic:

Respiratory:

Contraindication to Reserpine (Serpasil):

Warnings and precautions

CNS effects

Orthostatic hypotension

Asthma

Gallstones

Gastrointestinal Disease:

Parkinson disease

Renal impairment